Logo image of NKTR

NEKTAR THERAPEUTICS (NKTR) Stock Analyst Ratings

USA - Nasdaq - NASDAQ:NKTR - US6402683063 - Common Stock

51.12 USD
-6.62 (-11.47%)
Last: 12/11/2025, 8:00:02 PM
51.6401 USD
+0.52 (+1.02%)
After Hours: 12/11/2025, 8:00:02 PM
Buy % Consensus

86

ChartMill assigns a Buy % Consensus number of 86% to NKTR. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 109.43. This target is 114.07% above the current price.
NKTR was analyzed by 14 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about NKTR.
In the previous month the buy percentage consensus was at a similar level.
NKTR was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
NKTR Historical Analyst RatingsNKTR Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -108 -98 -88 -78 -68 -58 -48 -38 -28 -18 -8 5 10 15 20

Price Target & Forecast

Price Low Median Mean High 51.1298.98107.10109.43127.05 - 93.62% 109.51% 114.07% 148.53%
NKTR Current Analyst RatingNKTR Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5
Up and Down Grades
Date Firm Action Rating
2025-11-26 Citigroup Initiate Buy
2025-11-26 Jefferies Maintains Buy -> Buy
2025-09-23 B. Riley Securities Maintains Buy -> Buy
2025-09-19 BTIG Reiterate Buy -> Buy
2025-07-08 B. Riley Securities Maintains Buy -> Buy
2025-06-24 HC Wainwright & Co. Maintains Buy -> Buy
2025-04-11 Jefferies Upgrade Hold -> Buy
2025-03-14 Oppenheimer Upgrade Perform -> Outperform
2025-03-13 HC Wainwright & Co. Reiterate Buy -> Buy
2025-02-25 HC Wainwright & Co. Reiterate Buy -> Buy
2025-01-13 HC Wainwright & Co. Reiterate Buy -> Buy
2025-01-08 B. Riley Securities Initiate Buy
2024-11-04 Piper Sandler Initiate Overweight
2024-03-06 Jefferies Maintains Hold -> Hold
2023-11-20 JP Morgan Reiterate Underweight
2023-11-09 TD Cowen Upgrade Market Perform -> Outperform
2023-08-07 Mizuho Reiterate Neutral
2023-05-10 Jefferies Upgrade Underperform -> Hold
2023-03-06 Oppenheimer Maintains Perform
2023-02-27 Goldman Sachs Maintains Sell
2023-02-24 SVB Leerink Maintains Market Perform
2023-02-24 Jefferies Downgrade Hold -> Underperform
2022-08-08 JP Morgan Downgrade Neutral -> Underweight
2022-04-18 Mizuho Maintains Neutral
2022-04-18 SVB Leerink Maintains Market Perform
2022-04-18 Goldman Sachs Downgrade Neutral -> Sell
2022-03-09 Oppenheimer Upgrade Perform -> Outperform
2021-11-08 Benchmark Upgrade Hold -> Buy
2021-11-08 SVB Leerink Maintains Market Perform
2021-11-05 Oppenheimer Maintains Perform

NEKTAR THERAPEUTICS / NKTR FAQ

Can you provide the average price target for NEKTAR THERAPEUTICS stock?

14 analysts have analysed NKTR and the average price target is 109.43 USD. This implies a price increase of 114.07% is expected in the next year compared to the current price of 51.12.


How do analysts rate NEKTAR THERAPEUTICS (NKTR)?

The consensus rating for NEKTAR THERAPEUTICS (NKTR) is 85.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.


How many analysts have analysed NEKTAR THERAPEUTICS (NKTR)?

The number of analysts covering NEKTAR THERAPEUTICS (NKTR) is 14.